A recent study showed that the dual SGLT1/2 inhibitors may protect patients with diabetes from MI and stroke better, while the beneficial effects in patients without diabetes require more evaluation (Pitt and Bhatt, 2021). This evidence concerns the gene SLC5A1 and diabetes mellitus.